THC Rallies After Earnings as Street Lifts Targets Across the Board

Tenet Healthcare has reversed the defensiveness flagged in last week's preview: the stock gained 1.8% on the week to $266.69, options hedging has unwound sharply, and analysts have responded to the earnings print with a broad sweep of target increases.

The most telling shift this week is in options. The put/call ratio has dropped to 0.90, now running slightly below its 20-day average of 0.94, a z-score of just -0.61. That is a meaningful reversal from the October 28 preview, which had the ratio at 1.00 and 2.6 standard deviations above its mean, the most defensive reading in months. The hedging that built ahead of the October 29 earnings print has largely come off. The lending market remains completely unconcerned: short interest has fallen 8.6% on the week to 2.0% of the free float, borrow availability is an effectively unlimited 5,049% of short interest, and cost to borrow, while up 13% on the week, is still only 0.35%. There is no short-side pressure here.

The analyst response to earnings has been uniformly positive. Every firm that moved in the past 72 hours raised its price target, none cut ratings. Barclays lifted its target from $271 to $297 while keeping Overweight. Truist took its target to $305 from $290, Keybanc moved to $300 from $270, and Wells Fargo pushed to $321 from $281. Leerink Partners went furthest, raising to $342 from $309. The consensus mean now sits at $304, implying about 14% upside from the current price. Valuation remains undemanding: the trailing P/E is 12.8 and EV/EBITDA is 7.7. Factor scores reinforce the value case, with earnings yield and EV/EBIT both ranked in the top 10% of the ORTEX universe, and analyst recommendation divergence at the 94th percentile, meaning the Street is more uniformly bullish on THC than on nearly any peer.

The bull and bear cases remain structurally unchanged. Bulls point to the USPI ambulatory surgery segment, which carries higher margins and faster growth than the acute hospital business, alongside strong demand trends and an improving payer mix. Bears focus on the looming expiration of ACA subsidies, which analysts estimate could strip coverage from 80 to 85% of the affected patient population, creating a potential $220 million headwind to the Acute segment and $30 million to USPI in 2026. The October earnings print itself produced only a modest 1.8% next-day gain, suggesting the market acknowledged a solid quarter without pricing in a resolution of the subsidy risk.

Insider activity warrants a note of caution. The SEC EDGAR data shows net sales of roughly 186,000 shares over the past 90 days, worth close to $50 million. CEO Saumya Sutaria sold around $13.7 million of stock in late August at prices between $273 and $275, above the current level. The COO and two directors also sold in August and September, all without 10b5-1 plans disclosed. None of these trades were small. The pattern does not invalidate the bull thesis, but it is a contrast worth holding alongside the unanimous analyst optimism. T. Rowe Price remains the largest holder at nearly 11% of shares, and BlackRock lifted its stake to just over 10%, filing an amended 13G in early September. No 13D activist is on the register.

Wikipedia attention for THC was running at a z-score of 2.2 against its own trailing 90-day history as of late October, the highest retail attention reading in the alt-data coverage, though none of the available datasets have been measured to lead reported financials. The next earnings event is not until February 9, 2027, leaving 97 days for the subsidy expiration debate and the USPI trajectory to play out against an analyst community that, for now, is unanimously pointing higher.